REVVITY, INC.
Company Stats
- Market Cap
- $17.1B
- as of Sep 30, 2026
- Enterprise Value
- $19.4B
- Shares Outstanding
- 111.6M
- Free Float
- 99.5%
Income Statement
- Revenue
- $2.9B
- Operating Income
- $356.6M
- Net Income
- $241.2M
- EBITDA
- $762.0M
- Non-cash Impairment
- $4.8M
- FCF Margin, 3Y Avg
- 12.6%
- FCF Margin, Worst Year
- 0.4%
Cash Flow
- Free Cash Flow
- $509.4M
- FCF Yield
- 3.0%
- Owner FCF Yield
- 2.9%
Balance Sheet
- Cash & Equivalents
- $919.9M
- Total Debt
- $3.2B
- Net Debt
- $2.3B
- Net Debt / EBITDA
- 3.04x
- EV / EBITDA
- 25.43x
- Net Debt / EBIT
- 6.50x
Returns & Capital
- Dividends Paid
- $32.8M
- Dividend Yield
- 0.2%
- Dividend Payout, 3Y Avg
- 10.5%
- Share Repurchases
- $820.8M
- Buyback Yield, 3Y Avg
- 3.1%
- SBC, 3Y Avg
- $34.0M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $2.9B | $509.4M | 17.8% |
| FY2024 | $2.8B | $541.7M | 19.7% |
| FY2023 | $2.8B | $9.9M | 0.4% |
| FY2023 | $3.3B | $594.2M | 17.9% |
| FY2022 | $3.8B | $1.3B | 34.6% |
Annual filing data through FY ended December 28, 2025; shares and float as of October 16, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back
Revvity to Divest China Immunodiagnostics Business